Radiolabeled amino acids: basic aspects and clinical applications in oncology

PL Jager, W Vaalburg, J Pruim… - Journal of nuclear …, 2001 - Soc Nuclear Med
As the applications of metabolic imaging are expanding, radiolabeled amino acids may
gain increased clinical interest. This review first describes the basic aspects of amino acid …

[PDF][PDF] Indium-111–labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer

…, DJ van Veldhuisen, DT Sleijfer, PL Jager… - Journal of clinical …, 2006 - Citeseer
Purpose The cardiac and antineoplastic effects of trastuzumab may be related to specific
uptake of trastuzumab in myocardium and tumor tissue, respectively. We evaluated whether …

[18F]FLT-PET in oncology: current status and opportunities

…, AJH Suurmeijer, DCP Cobben, PL Jager… - European journal of …, 2004 - Springer
In recent years, [ 18 F]-fluoro-3′-deoxy-3′-L-fluorothymidine ([ 18 F]FLT) has been
developed as a proliferation tracer. Imaging and measurement of proliferation with PET could …

Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model

…, W Vaalburg, EFJ de Vries, PL Jager… - Journal of Nuclear …, 2004 - Soc Nuclear Med
Increased glucose metabolism of inflammatory tissues is the main source of false-positive
18 F-FDG PET findings in oncology. It has been suggested that radiolabeled nucleosides …

Preclinical characterisation of 111In‐DTPA‐trastuzumab

…, AJH Suurmeijer, S de Jong, PL Jager… - British journal of …, 2004 - Wiley Online Library
Trastuzumab (Herceptin®) is a recombinant humanised IgG1 monoclonal antibody against
the human epidermal growth factor receptor 2 (HER2), used for metastatic breast cancer …

Esophageal Cancer: CT, Endoscopic US, and FDG PET for Assessment of Response to Neoadjuvant Therapy—Systematic Review1

…, OS Hoekstra, J Stoker, P Fockens, PL Jager… - Radiology, 2005 - pubs.rsna.org
PURPOSE: To compare diagnostic accuracy of computed tomography (CT), endoscopic
ultrasonography (US), and fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography …

Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study

…, ANA van der Horst-Schrivers, PL Jager - The lancet …, 2006 - thelancet.com
Background To assess individual treatment options for patients with carcinoid tumours, accurate
knowledge of tumour localisation is essential. We aimed to test the diagnostic sensitivity …

[PDF][PDF] Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission …

…, K Vanghillewe, AH Brouwers, PL Jager… - Journal of clinical …, 2008 - researchgate.net
Jager, and Elisabeth GE de Vries … Jager, Elisabeth GE de Vries Manuscript writing: Klaas
P. Koopmans, Oliver C. Neels, Ido P. … Neels OC, Jager PL, Koopmans KP, et al: Development …

6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications

PL Jager, R Chirakal, CJ Marriott… - Journal of nuclear …, 2008 - Soc Nuclear Med
In recent years, 6-l- 18 F-fluorodihydroxyphenylalanine ( 18 F-DOPA) PET has emerged as a
new diagnostic tool for the imaging of neuroendocrine tumors. This application is based on …

Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis

…, EB Haagsma, PN Hawkins, PL Jager - The American journal of …, 2006 - Elsevier
PURPOSE: To assess the diagnostic accuracy and additional information provided by 123 I-labeled
serum amyloid P component (SAP) scintigraphy in patients with systemic and …